在BRCA1/BRCA2-突变乳腺癌中具有药物的分子网络
Francesca Pia Carbone1, Pietro Ancona1, Stefano Volinia1,2,3
1Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Biology
|March 26, 2025
概括
在BRCA1和BRCA2突变驱动激进的三阴性乳腺癌. 这项研究确定了放松调节的基因和疗法,强调了铁和蛋白质糖途径作为改善治疗结果的潜在药物标.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 瘤抑制基因BRCA1和BRCA2的突变与侵袭性三阴性乳腺癌 (TNBC) 有关.
- TNBC的特点是缺少雌激素,孕和人体表皮生长因子受体2,因此难以治疗.
研究的目的:
- 阐明BRCA1/BRCA2突变背后的代谢和遗传联系.
- 探索这些突变与有效的治疗策略之间的关系.
- 为了确定BRCA突变癌症的新药标.
主要方法:
- 使用Cytoscape软件构建基因网络的PubMed-NCBI文章的文献分析.
- 通过BRCA突变放松调节的基因和通过治疗方法调节的基因的识别.
- 针对BRCA1/BRCA2突变细胞的向疗法的疗效评估.
主要成果:
- 发现98个基因被BRCA突变放松调节,其中24个基因被疗法调节.
- 特定的基因如BIRC5,SIRT1,MYC,EZH2,CSN2 (BRCA1) 和BCL2,BAX,BRIP1 (BRCA2) 已被确定.
- 诸如CDDO-Imidazolide,resveratrol,3-deazaneplanocin A,genistein,daidzein和PARP抑制剂等疗法对BRCA突变细胞具有选择性的疗效.
- 铁和蛋白质甘氨酸通路成为潜在的治疗点.
结论:
- BRCA1/BRCA2突变会产生弱点,这些弱点可以通过向疗法加以利用.
- 了解基因网络和途径改变对于开发TNBC有效治疗至关重要.
- 铁和蛋白质糖途径代表了未来在BRCA突变癌症中药物开发的有希望的途径.
关键词:
这就是BRCA1的原因.这就是BRCA2的原因.在巴黎的巴黎.乳腺癌 乳腺癌 乳腺癌药物 药物 药物 药物 药物 药物突变是发生在突变中的突变.路径路径路径路径路径植物性雌激素是一种植物性雌激素.更多相关视频
相关概念视频
Protein Networks
3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
Drug Discovery: Overview
7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
Targets for Drug Action: Overview
5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
Protein-protein Interfaces
12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K
Drug-Receptor Bonds
2.6K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.6K
Drug-Receptor Interactions
4.7K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.7K


